Antibodies can be conjugated to effector molecules to derive targeted therapeutics with properties such as cell-specific cytotoxicity. The murine anti-CD22 antibody RFB4 linked to a member of the ribonuclease A superfamily, Onconase (Onc), becomes a potential drug candidate for non-Hodgkin's lymphoma. Onc is currently in Phase III clinical trials for unresectable malignant mesothelioma but conjugation to RFB4 considerably enhances its specificity for CD22+ lymphomas. RFB4-targeted Onc is effective in preclinical models, causes little non-specific toxicities in mice, and has favorable formulation properties. Derivatization and conjugation of RFB4 and Onc have been optimized.
CITATION STYLE
Newton, D. L., Stockwin, L. H., & Rybak, S. M. (2009). Anti-CD22 Onconase: preparation and characterization. Methods in Molecular Biology (Clifton, N.J.), 525. https://doi.org/10.1007/978-1-59745-554-1_22
Mendeley helps you to discover research relevant for your work.